Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH

Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will re...

Descripción completa

Detalles Bibliográficos
Autor principal: Weitz, Ilene Ceil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066888/
https://www.ncbi.nlm.nih.gov/pubmed/37016661
http://dx.doi.org/10.2147/JBM.S362220
_version_ 1785018345625485312
author Weitz, Ilene Ceil
author_facet Weitz, Ilene Ceil
author_sort Weitz, Ilene Ceil
collection PubMed
description Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.
format Online
Article
Text
id pubmed-10066888
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100668882023-04-03 Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH Weitz, Ilene Ceil J Blood Med Review Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH. Dove 2023-03-29 /pmc/articles/PMC10066888/ /pubmed/37016661 http://dx.doi.org/10.2147/JBM.S362220 Text en © 2023 Weitz. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Weitz, Ilene Ceil
Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
title Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
title_full Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
title_fullStr Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
title_full_unstemmed Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
title_short Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
title_sort pegcetacoplan: a new opportunity for complement inhibition in pnh
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066888/
https://www.ncbi.nlm.nih.gov/pubmed/37016661
http://dx.doi.org/10.2147/JBM.S362220
work_keys_str_mv AT weitzileneceil pegcetacoplananewopportunityforcomplementinhibitioninpnh

Ejemplares similares